ATAI Life Sciences N.V. financial data

Symbol
ATAI on Nasdaq
Industry
Pharmaceutical Preparations
Location
Wallstrasse 16, Berlin, Germany
State of incorporation
Netherlands
Fiscal year end
December 31
Former names
ATAI Life Sciences B.V. (to 6/21/2021)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 879 % -34.1%
Debt-to-equity 20.2 % +23.1%
Return On Equity -25.7 % +55%
Return On Assets -21.4 % +56.4%
Operating Margin -29.2K % +43.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 168M shares +1.08%
Common Stock, Shares, Outstanding 168M shares +1.06%
Entity Public Float 203M USD -50.5%
Common Stock, Value, Issued 18.8M USD +1.05%
Weighted Average Number of Shares Outstanding, Basic 160M shares +2.95%
Weighted Average Number of Shares Outstanding, Diluted 160M shares +2.95%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 378K USD +39%
General and Administrative Expense 59M USD -10.2%
Operating Income (Loss) -110M USD +21.9%
Nonoperating Income (Expense) 53M USD +1296%
Income Tax Expense (Benefit) 681K USD -89.5%
Net Income (Loss) Attributable to Parent -58.1M USD +60%
Earnings Per Share, Basic -0.36 USD/shares +60.9%
Earnings Per Share, Diluted -0.36 USD/shares +60.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.3M USD -86.3%
Other Assets, Current 899K USD -37.4%
Assets, Current 118M USD -51.4%
Other Long-term Investments 32.4M USD +711%
Property, Plant and Equipment, Net 873K USD -16.3%
Operating Lease, Right-of-Use Asset 1.04M USD -23.7%
Other Assets, Noncurrent 2.43M USD -25.6%
Assets 216M USD -14.9%
Accounts Payable, Current 3.81M USD -1.17%
Accrued Liabilities, Current 12.9M USD +0.44%
Liabilities, Current 17.6M USD -1.57%
Operating Lease, Liability, Noncurrent 838K USD -23.5%
Other Liabilities, Noncurrent 8.26M USD +194%
Liabilities 47.2M USD +24.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -19.2M USD +7.91%
Retained Earnings (Accumulated Deficit) -635M USD -10.1%
Stockholders' Equity Attributable to Parent 168M USD -21%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 169M USD -21.8%
Liabilities and Equity 216M USD -14.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.6M USD -6.93%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 11.5M USD -28.4%
Common Stock, Shares Authorized 750M shares 0%
Common Stock, Shares, Issued 168M shares +1.06%
Common Stock, Par or Stated Value Per Share 0.11 USD/shares -8.33%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.2M USD -136%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 34.3M USD -75.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 629K USD +39.2%
Deferred Tax Assets, Valuation Allowance 90M USD -5.97%
Deferred Tax Assets, Gross 121M USD +19.5%
Operating Lease, Liability 1.08M USD -24%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -56.4M USD +61%
Operating Lease, Liability, Current 239K USD -25.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Unrecognized Tax Benefits 369K USD
Additional Paid in Capital 803M USD +1.46%
Depreciation, Depletion and Amortization 83K USD +27.7%
Deferred Tax Assets, Net of Valuation Allowance 30.8M USD +473%
Interest Expense 2.77M USD +25.5%